Terumo Interventional Oncology Division presents Occlusafe, a novel micro-balloon catheter for enhanced transarterial embolization effects.1
Balloon TACE (B-TACE) with Occlusafe was developed to further improve the local control effects (flow redistribution) by altering hemodynamics under balloon occlusion.2
Occlusafe allows you to redistribute the flow in such way that therapeutics agents are preferentially accumulated in the targeted lesion.
Accurate navigability allows for segmental and sub-segmental catheter positioning with Terumo hydrophilic coating.
Dead volume space is 0.30 ml
(0.90 mm / 0.94 mm)
Including connector part
All sizes of LifePearl could pass through the Occlusafe without big friction.3
Please quote above item reference codes when placing an order.
Occlusafe is not available for sale in all countries. Please contact your Terumo local sales representative for more information. Occlusafe has not been approved by the FDA and is therefore not available for sale in the U.S.A.
1 Hriotaka Arai; Hepatology Research 2015; 45, 663-666. The therapeutic effects of B-TACE were significantly higher than those of C-TACE, and improved drug uptake into cancer nodules was observed.
2 Ishikawa T (2014):Predictive factor of local recurrence after balloon-occluded Tace with miriplatin(MPT) in hepatocellular carcinoma.PLoS ONE 9(7): e103009.doi:10.1371/journal.pone.0103009.
3 - Terumitsu Hasebe (2015): Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization, Minimally Invasive Therapy & Allied Technologies, DOI: 10.3109/13645706.2015.1086381. - Terumitsu Hasebe; Minimally Invasive Therapy & Allied Technologies. 2015 Apr;24(2):94-100. doi: 10.3109/13645706.2014.951657. Epub 2014 Sep 29. PubMed. - Data on files. Reference OS-003. Terumo Europe NV - Hirotaka Arai; Hepatology Research 2015; 45: 6 –6 63 66 - Hirotaka Arai; Hepatology Research 2015; 45: 6 –6 63 67
4 Nobuyuki Takahashi: Cardiovasc Intervent Radiol (2013), 36:706-713.